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ABSTRACT
Ceftobiprole, an investigational b-lactam antibiotic, has been shown to have a broad spectrum of activity
against Gram-positive and Gram-negative pathogens. Unlike currently available b-lactams, ceftobiprole
has been shown to be active against methicillin-resistant staphylococci because of its high affinity for
penicillin-binding protein (PBP) 2¢ (2a). Ceftobiprole has undergone extensive evaluation in phase I
studies to characterise dose, pharmacokinetics, and safety ⁄ tolerability. In an early phase II study, all 35
clinically evaluable patients (n ¼ 40) with complicated skin and skin structure infections (cSSSIs)
receiving intravenous ceftobiprole 750 mg twice-daily were cured, including four of four patients with
methicillin-resistant Staphylococcus aureus (MRSA). Microbiological eradication was achieved in 91%
(21 ⁄ 23) of evaluable patients. On the basis of these results, phase III studies of ceftobiprole for the
treatment of cSSSIs were initiated. One study compared intravenous ceftobiprole (500 mg every 12 h) to
intravenous vancomycin (1 g every 12 h) in patients with cSSSIs due to Gram-positive bacteria.
Staphylococci were the predominant pathogens, and more than 25% of the microbiologically evaluable
patients had infections caused by MRSA. In the clinically evaluable population, efficacy and adverse
events were comparable between treatment arms. Additional clinical trials in cSSSI and pneumonia
patients are underway to evaluate ceftobiprole for the treatment of infections due to both Gram-positive
and Gram-negative bacteria. Ceftobiprole is the first cephalosporin to demonstrate clinical efficacy in
patients with infections due to methicillin-resistant staphylococci and, if approved by regulatory
authorities, is expected to be a useful addition to the armamentarium of agents for the treatment of
complicated skin infections and pneumonia.
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INTRODUCTION
Ceftobiprole is a novel, extended-spectrum cep-
halosporin with potent activity against Gram-
negative and Gram-positive pathogens. The major
advantage of ceftobiprole compared with older
cephalosporins is its bactericidal activity against
certain b-lactam-resistant Gram-positive patho-
gens, such as methicillin-resistant Staphylococcus
aureus (MRSA) and penicillin-resistant and ceftri-
axone-resistant Streptococcus pneumoniae. Ceftobi-
prole has also been shown to be active against a
broad spectrum of clinically important Gram-
negative pathogens, including most extended-
spectrum b-lactamase-negative Enterobacteria-
ceae and Pseudomonas aeruginosa.
As is the case with all b-lactams, the binding of
ceftobiprole to penicillin-binding proteins (PBPs)
is a critical determinant of its antibacterial activity.
The potent and long-lasting inhibition of PBP2¢
(2a) of S. aureus, however, distinguishes ceftobi-
prole from other commercially available b-lactams
and is the molecular basis for its activity against
methicillin-resistant staphylococci. The inhibition
mechanism has been studied and includes analy-
ses of the crystal structure of ceftobiprole in
complex with the purified PBP2¢ (16th ECCMID,
abstract P-1586) (Fig. 1). Ceftobiprole binds tightly
into the active site of PBP2¢ and rapidly forms a
stable acyl–enzyme complex. This interaction
results in very slow hydrolysis of the molecule
that, in turn, results in the stable inhibition of this
enzyme. This inhibition, along with ceftobiprole’s
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interaction with the full complement of staphylo-
coccal PBPs, results in the bactericidal activity that
ceftobiprole has demonstrated against staphylo-
cocci. The broad-spectrum activity of ceftobiprole
has been demonstrated against many clinical
isolates. The activity of ceftobiprole against
Gram-positive bacteria that were isolated from
patients in a recently completed trial involving
patients with complicated skin and skin structure
infections (cSSSIs) (Fig. 2a) (46th ICAAC, abstract
E-116) is consistent with previously published
data showing low MICs against a broad spectrum
of pathogens, including MRSA, coagulase-negat-
ive staphylococci and Streptococcus spp. [1]. These
data strongly support the conclusion that the
majority of clinically important Gram-positive
bacteria will have MIC values for ceftobiprole at
or below 2 mg ⁄L.
Ceftobiprole also inhibits a wide range of
Gram-negative pathogens (Fig. 2b). Analysis of
in-vitro activity against a collection of Enterobac-
teriaceae (n ¼ 372) from hospitalised patients
indicated that 93% of pathogens had MIC values
at or below 4 mg ⁄L (15th ECCMID, abstract
P-1569). In-vitro activity of ceftobiprole against
P. aeruginosa has been shown to be comparable to
that demonstrated for ceftazidime and cefepime.
In a study assessing 741 isolates of P. aeruginosa,
72% of isolates were inhibited by 4 mg ⁄L or less
of ceftobiprole, compared with 68% and 73% of
isolates being inhibited by 4 mg ⁄L or less of
cefepime and ceftazidime, respectively (46th ICA-
AC, abstract E-115).
PHASE I AND II CLINICAL STUDIES
Extensive evaluation of healthy volunteers in
phase I studies was undertaken to explore safety
and tolerability, pharmacokinetics and dosing.
Eight phase I studies were completed, involving a
Fig. 1. Crystal structure of ceftobi-
prole bound to the active site of
Staphylococcus aureus penicillin-
binding protein 2¢. Courtesy of
M. Page, Basilea Pharmaceutica Ltd,
Basel, Switzerland.
0
25
50
75
100
125
150
175
200
225
250
275
≤0.06 0.12 0.25 0.5 1 2 4 8 ≥16
MIC (mg/L)
N
um
be
r o
f i
so
la
te
s
Other Gram-positive cocci
Streptococcus spp.
β-Haemolytic streptococci, not group A,B
S. agalactiae
S. pyogenes
CoNS MR
CoNS MS
MRSA
MSSA
Enterococcus faecium
Enterococcus faecalis
Bacillus spp.
(a) 160
140
120
100
80
60
40
20
0
<0.06 0.06 0.12 0.25 0.5 1 2 168 >324 32
MIC (mg/L)
N
um
be
r o
f i
so
la
te
s
Serratia marcescens
Proteus mirabilis
Klebsiella pneumoniae
Klebsiella oxytoca
Escherichia coli
Enterobacter cloacae
Enterobacter aerogenes
Citrobacter koseri
Citrobacter freundii
93% Susceptible
1%  Intermediate
6% Resistant
N = 372 isolates(b)
Fig. 2. Ceftobiprole activity against (a) Gram-positive (46th ICAAC, abstract E-116) and (b) Gram-negative (Enterobac-
teriaceae) isolates (15th ECCMID, abstract P-1569). CoNS MR, methicillin-resistant ⁄ coagulase-negative staphylococci;
CoNS MS, methicillin-susceptible ⁄ coagulase-negative staphylococci; MRSA, methicillin-resistant Staphylococcus aureus;
MSSA, methicillin-susceptible S. aureus.
26 Clinical Microbiology and Infection, Volume 13 Supplement 2, 2007
 2007 The Author
Journal Compilation  2007 Clinical Microbiology and Infectious Diseases, CMI, 13 (suppl 2), 25–29
total of 133 healthy volunteers (14th ECCMID,
abstract P-1030) [2,3]. Doses ranging from 125 to
1000 mg were evaluated in single-dose studies
and multiple ascending-dose studies, including
two studies in which ceftobiprole was adminis-
tered three-times-daily (500 mg every 8 h) for up
to 12 days.
The pharmacokinetic profile that has emerged
from these studies shows that ceftobiprole me-
docaril, the water-soluble prodrug, is rapidly
converted to the active drug [2]. As for other
b-lactams, the pharmacokinetic parameter that
correlates best with efficacy against MRSA and
penicillin-resistant S. pneumoniae is the time for
which concentrations of free drug remain above
the MIC for the infecting pathogen (ƒT > MIC)
(40th ICAAC, abstract 1079). Phase I trials have
shown that administration of single and multiple
ascending doses of ceftobiprole results in propor-
tional increases in AUC and Cmax. During repea-
ted administration of the prodrug (750 mg-
equivalent of ceftobiprole twice-daily), there was
negligible drug accumulation. As with other
cephalosporins, the major distribution of this
molecule at steady state appears to be in the
extracellular space, and ceftobiprole is excreted
primarily unchanged in the urine, with nearly all
of the drug recovered within hours of dosing [2].
Pharmacokinetic data from a single-ascending-
dose study support these findings and indicate
that the AUC and Cmax of ceftobiprole are dose-
proportional over the entire dose range of 125–
1000 mg (Fig. 3) [2]. The pharmacokinetics of
ceftobiprole in patients enrolled in the phase II
trial were consistent with those in healthy volun-
teers (Table 1) (14th ECCMID, abstract P-1031).
As expected, on the basis of the renal clearance of
ceftobiprole, renally impaired patients will re-
quire dose adjustment. On the basis of a phase I
trial in renally impaired subjects, it has been
possible to propose dose adjustments based on
creatinine clearance values (14th ECCMID, ab-
stract P-1032).
A small phase II open-label, non-comparative
trial focused on treatment of patients with cSSSIs
caused by Gram-positive pathogens has been
completed (44th ICAAC, abstract L-361). Most
patients enrolled in this trial had infections
caused by streptococci or staphylococci, including
methicillin-resistant strains. On the basis of phar-
macokinetic modelling involving healthy volun-
teers, and because the focus of the trial was
infections caused by Gram-positive bacteria, a
regimen of ceftobiprole 750 mg twice-daily for 7–
14 days was used. The patient population includ-
ed intravenous drug users (68%, n ¼ 22) who
were known to be at high risk of infections due to
MRSA. Among the 23 microbiologically evaluable
patients, 15 had infections due to S. aureus,
including four infections due to MRSA. Other
infecting Gram-positive bacteria included other
staphylococcal species (n ¼ 2) and streptococcal
species (n ¼ 6). Microbiological eradication was
achieved in 91% (21 ⁄ 23) of microbiologically
evaluable patients. Clinical cure was achieved in
all 34 clinically evaluable patients, including the
four patients with infections due to MRSA.
Collective data from these phase I and II
studies supported the conclusion that ceftobiprole
is safe and well-tolerated. The most frequent
drug-related adverse event reported during these
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Fig. 3. AUC and Cmax of single ascending doses of
ceftobiprole prodrug [3].
Table 1. Summary of ceftobiprole pharmacokinetics (14th
ECCMID, abstract P-1031)
Parameter
Study day 7
cSSSI patients
n = 24
Study day 7
Healthy volunteers
n = 24
AUCINF (mgÆh ⁄L) 143 (±39.5) 165 (±12.8)
AUClast (mgÆh ⁄L) 133 (±34.7) 156 (±11.1)
Cmax (mg ⁄L) 57.9 (±29.4) 60.6 (±9.99)
t1 ⁄ 2 b (h) 3.06 (±0.62) 4.11 (±0.41)
Vss (L) 20.1 (±5.16) 15.7 (±1.91)
Cls (L ⁄h) 5.99 (±1.74) 4.84 (±0.34)
Urinary recoverya
(% of dose)
82.1 (±27.4) 84.4 (±9.23)
Values are presented as arithmetic means (± SD).
a0–12 h recovery.
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trials was a transient taste disturbance during
infusion. Other commonly reported adverse
events were nausea and vomiting [3].
RATIONAL DOSE SELECTION
A recent analysis using pharmacokinetic data
from phase I and II clinical studies (n ¼ 150) was
conducted to determine the probability of attain-
ing critical targets with two different dosing
regimens: 500 mg intravenously every 8 h as a
2-h infusion, and 500 mg intravenously every
12 h as a 1-h infusion (16th ECCMID, abstract P-
1524) [4]. Monte Carlo simulations were per-
formed, considering MIC values from 0.25 mg ⁄L
to 8 mg ⁄L and targets of maintaining free drug
concentrations in excess of the MIC for 30–60% of
the dosing interval (16th ECCMID, abstract P-
1524) [4].
This analysis predicted a high probability of
exceeding targets for key Gram-positive bacteria,
including MRSA, with a dose regimen of 500 mg
intravenously every 12 h as a 1-h infusion, and of
meeting or exceeding targets for Enterobacteria-
ceae and P. aeruginosa with a regimen of 500 mg
every 8 h administered via 2-h infusion. On the
basis of these results, both of these regimens were
selected for testing in phase III trials. In the first of
these phase III trials, which was focused on
treatment of patients with cSSSIs due to Gram-
positive bacteria, the intravenous 500 mg every
12 h regimen was used.
PHASE II I DATA
A phase III clinical trial that compared the clinical
outcome following ceftobiprole treatment with
that of vancomycin in patients with cSSSIs due to
suspected or proven Gram-positive infection
was recently completed (46th ICAAC, abstract
L-1212). Subjects were hospitalised patients with
cSSSIs involving deep soft tissue or those requir-
ing surgical intervention and having at least one
of the following: infection occurring within
30 days at the site of a trauma or surgery, an
onset of abscess within 7 days, or an onset of
cellulitis within 7 days.
Patients were randomly assigned to either
500 mg of ceftobiprole by 60-min intravenous
infusion every 12 h, or 1 g of vancomycin by 60-
min intravenous infusion every 12 h. Therapy
continued for 7–14 days. Clinical and microbiolo-
gical evaluations were performed at baseline and
on days 4, 8 and 14 and ⁄ or within 24 h of ending
therapy.
Preliminary analysis of the data indicated that
ceftobiprole was not inferior to the comparator
regimen (Table 2). The overall clinical cure rates
were 93.3% for ceftobiprole (n ¼ 397) and 93.5%
for vancomycin (n ¼ 387). In a sub-analysis of
patients infected with MRSA (n ¼ 179), cure rates
were also similar between the treatment arms:
91.8% for ceftobiprole and 90.0% for vancomycin.
With regard to tolerability, incidences of serious
adverse events (AEs), treatment-limiting AEs
and treatment-emergent AEs were comparable
between the two treatment arms. Four per cent
(17 ⁄ 389) of the patients receiving ceftobiprole
discontinued treatment because of an AE, com-
pared with 6% (22 ⁄ 382) receiving vancomycin.
Phase III trials in patients with cSSSIs, includ-
ing those with suspected or proven Gram-negat-
ive and ⁄ or Gram-positive infection, and in
patients with pneumonia, are ongoing.
CONCLUSION
Ceftobiprole is a cephalosporin with demonstrat-
ed in-vitro and in-vivo activity against a broad
spectrum of clinically important bacteria, includ-
ing MRSA. Clinical data support the conclusion
that ceftobiprole is highly effective in treating
patients with cSSSIs caused by Gram-positive
pathogens, including MRSA. No clinically rele-
vant safety concerns have been reported in trials
to date, which have included nearly 500 patients.
Ongoing trials are aimed at confirming the clinical
and microbiological efficacy of ceftobiprole for
serious infections due to Gram-positive and
Gram-negative pathogens. Its activity against
clinically important pathogens, together with its
safety and tolerability, support its potential use as
empirical treatment for infections in the hospital
setting.
Table 2. Preliminary efficacy results of a ceftobiprole
phase III study (J&J PRD internal data)
Ceftobiprole Vancomycin
Overall clinical cure 93.3% 93.5%
Cure rate in subjects
with MRSA
91.9% 90.0%
MRSA, methicillin-resistant Staphylococcus aureus.
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